BioInvent is a company with a long history and a strong position in the generation and development of antibody drugs. The foundation of the company is expertise in immunology, cancer biology and antibody biology.
1997-2002
BioInvent’s exciting journey towards new antibody cancer drugs began. The antibody library n-DeCoDeR® was developed. Stockholm Stock Exchange listing in 2001. In 2002, the development of its own pharmaceutical projects was started.
2003-2017
Drug development projects in a number of areas and several outlicensing agreements performed.
2018
Martin Welschof is appointed CEO. Transformation initiated towards to a company fully focused on immuno-oncology and with a portfolio strategy.
2019-2022
Portfolio expands from one project in clinical development to five ongoing trials. Lead program BI-1206 presents promising clinical data in phase 1. BI-1206 is out-licensed to CASI Pharmaceuticals for China, Hong Kong, Macau and Taiwan.
2023
A broad portfolio with six programs ongoing in clinical development.